N39.498 Insurance Policy Changes

ICD-10 N39.498 is officially defined as "Other specified urinary incontinence." code N39.498 is referenced in 9 tracked payer policy changes from Excellus BlueCross BlueShield, Independence Blue Cross, and 2 other payers. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code N39.498 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Excellus BlueCross BlueShield · Effective Mar 19, 2026Medium impact
Bulking Agents for Treatment of Urinary or Fecal Incontinence 7.01.22
Urethral bulking agents may be considered medically appropriate for urinary incontinence when they are FDA-approved and the indication criteria are met. Collagen implants are covered for stress incontinence due to urethral sphincter dysfunction that is unresponsive to conservative therapy, with a listed indication such as congenital or acquired sphincter weakness or biological female patients with abdominal leak point pressure of 100 cm H2O or less. Bulking agents are covered for stress incontinence due to intrinsic sphincter deficiency only in biological female patients unresponsive to conservative therapy. Urethral bulking agents are not medically necessary for urinary retention with overflow incontinence, ectopic ureter, neurogenic bladder dysfunction, urinary fistulas, or psychogenic incontinence. Perianal bulking agents for fecal incontinence are investigational.
Independence Blue Cross · Effective Jan 1, 2026Medium impact
11.17.04z, Sacral Nerve Stimulation (SNS) and Posterior Tibial Nerve Stimulation (PTNS) for the Control of Incontinence
Independence Blue Cross reissued Policy 11.17.04z to add two new CPT codes (0988T and 0989T) as experimental/investigational effective 01/01/2026. These codes are excluded from coverage for all Independence Blue Cross products and are not eligible for reimbursement. The policy also reaffirms existing coverage criteria for sacral nerve stimulation (SNS) and posterior tibial nerve stimulation (PTNS) for incontinence treatment.
Aetna · Identified Aug 19, 2026Medium impact
YAG Laser in Ophthalmology and Other Selected Indications (CPB 0354, reviewed 2026-05-21)
Aetna considers Nd:YAG laser capsulotomy medically necessary after cataract extraction in members with visually significant clouding of the posterior capsule, and considers Nd:YAG laser peripheral iridotomy medically necessary for acute primary angle closure, primary angle-closure glaucoma, plateau iris syndrome, aqueous misdirection, and before intraocular lens insertion into the anterior chamber to avoid post-operative iris bombe or pupil block. Capsulotomy performed within 6 months of cataract surgery is subject to medical necessity review, and it is considered experimental, investigational, or unproven if none of the stated criteria is met. Nd:YAG laser vitreolysis for vitreous floaters, posterior hyaloidotomy for pre-macular hemorrhage, goniopuncture for failed trabeculectomy, and peripheral iridotomy to prevent pigment dispersion glaucoma are considered experimental, investigational, or unproven, as are many non-ophthalmological uses such as basal cell carcinoma, benign prostatic hyperplasia, onychomycosis and snoring.
Aetna · Identified Aug 18, 2026Medium impact
Urinary Incontinence (CPB 0223, reviewed 2026-07-16)
Aetna Clinical Policy Bulletin 0223 on urinary incontinence, reviewed 2026-07-16, considers multi-channel urodynamic studies medically necessary when a member has both symptoms and physical findings of urinary incontinence or voiding dysfunction and the provider is considering invasive, potentially morbid or irreversible treatment after conservative management has failed. It considers medically necessary the artificial urinary sphincter, FDA-cleared peri-urethral bulking agents, permanent sacral nerve stimulators after temporary trial stimulation, percutaneous tibial nerve stimulation, weighted vaginal cones, pessaries, tension-free and transobturator tape procedures, colposuspension and sub-urethral sling procedures when the stated criteria are met. Bilateral permanent sacral nerve stimulator implantation, the Genityte and FemiLift laser procedures, stem cell therapy and many other listed interventions are considered experimental, investigational or unproven.
Aetna · Identified Aug 14, 2026Medium impact
Pudendal Nerve Decompression (CPB 0805, reviewed 2025-11-20)
Aetna clinical policy bulletin 0805 considers pudendal nerve decompression experimental, investigational, or unproven for indications including chronic pelvic pain, interstitial cystitis, penile numbness and erectile dysfunction, persistent genital arousal disorder, pudendal neuralgia, and vulvodynia. The policy also considers pudendal nerve hydrodissection for chronic pelvic pain syndrome and urinary incontinence, and pudendal neurolysis for persistent genital arousal disorder and pudendal nerve entrapment syndrome, experimental, investigational, or unproven. The policy does not apply to pudendal nerve blocks used in obstetrics and other operative procedures.
Aetna · Identified Aug 12, 2026Medium impact
Organ Prolapse: Selected Procedures (CPB 0858, reviewed 2025-12-24)
Aetna considers dynamic MRI in persons with complex organ prolapse to supplement the physical examination, laparoscopic suture rectopexy for rectal prolapse, Le Fort colpocleisis for severe utero-vaginal prolapse in elderly and chronically ill persons who no longer desire coital function, sacrocolpopexy for vaginal apical prolapse repair, and tension-free vaginal tape for pelvic organ prolapse complicated by stress urinary incontinence medically necessary. Aetna considers biodegradable cog threads, biologic grafts for vaginal apical prolapse, combined laparoscopic-vaginal lateral suspension, pectopexy, laser therapy, transcutaneous electrical nerve stimulation, trans-vaginal absorbable meshes or biological grafts, vNOTES presacral-uterosacral hysteropexy, vNOTES uterosacral ligament suspension, vaginal tactile imaging, and genetic testing experimental, investigational, or unproven for pelvic organ prolapse. The covered CPT codes apply when the selection criteria are met, and specific CPT, HCPCS and ICD-10 codes are listed as not covered for the indications in the policy.
Blue Cross & Blue Shield of Mississippi · Identified Jun 20, 2026Medium impact
Injectable Bulking Agents for the Treatment of Urinary and Fecal Incontinence
Carbon-coated spheres, calcium hydroxylapatite, polyacrylamide hydrogel, or polydimethylsiloxane may be considered medically necessary to treat stress urinary incontinence in men and women who have failed appropriate conservative therapy. Autologous cellular therapy, autologous fat, autologous ear chondrocytes, and any other periurethral bulking agent, including Teflon, are investigational for stress urinary incontinence. Periurethral bulking agents for urge urinary incontinence and perianal bulking agents for fecal incontinence are also investigational.
Independence Blue Cross · Effective Jan 1, 2026Low impact
MA11.028l, Sacral Nerve Stimulation (SNS) and Posterior Tibial Nerve Stimulation (PTNS) for the Control of Incontinence
Independence Blue Cross reissued MA11.028l on 01/21/2026 to communicate the company's continuing position on Sacral Nerve Stimulation (SNS) and Posterior Tibial Nerve Stimulation (PTNS) for incontinence control. Two new experimental/investigational CPT codes (0988T and 0989T) were added effective 01/01/2026 and are NOT covered. No changes to existing coverage criteria or medically necessary procedures.
Aetna · Identified Nov 2, 2026Low impact
Pudendal Nerve Decompression (CPB 0805, reviewed 2026-10-28)
Aetna's clinical policy bulletin 0805 on pudendal nerve decompression was reviewed on 10/28/2026. It treats pudendal nerve decompression, hydrodissection and neurolysis as experimental, investigational or unproven for chronic pelvic pain, pudendal neuralgia, interstitial cystitis, penile numbness and erectile dysfunction, persistent genital arousal disorder and vulvodynia, and it lists three related CPT codes as not covered for those indications. The source does not state an effective date for a change or describe a coverage change in this review.

Watch N39.498

Get one email when a payer policy names N39.498, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

No account needed. We send a confirmation link first, and every email has a one-click stop link.

FREQUENTLY ASKED QUESTIONS

What insurance policy changes affect code N39.498?

There are 9 tracked policy changes affecting code N39.498, including updates from Excellus BlueCross BlueShield, Independence Blue Cross, Aetna. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code N39.498?

Payers that have issued tracked updates for code N39.498 include: Excellus BlueCross BlueShield, Independence Blue Cross, Aetna, Blue Cross & Blue Shield of Mississippi.

How do I get notified when code N39.498 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code N39.498. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code N39.498?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

All billing codes J3590 C9399 J3490 99215 99213 99202

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Bulking Agents for Treatment of Urinary or Fecal Incontinence 7.01.22

11.17.04z, Sacral Nerve Stimulation (SNS) and Posterior Tibial Nerve Stimulation (PTNS) for the Control of Incontinence

YAG Laser in Ophthalmology and Other Selected Indications (CPB 0354, reviewed 2026-05-21)

Urinary Incontinence (CPB 0223, reviewed 2026-07-16)

Pudendal Nerve Decompression (CPB 0805, reviewed 2025-11-20)

Organ Prolapse: Selected Procedures (CPB 0858, reviewed 2025-12-24)

Injectable Bulking Agents for the Treatment of Urinary and Fecal Incontinence

MA11.028l, Sacral Nerve Stimulation (SNS) and Posterior Tibial Nerve Stimulation (PTNS) for the Control of Incontinence

Pudendal Nerve Decompression (CPB 0805, reviewed 2026-10-28)

What insurance policy changes affect code N39.498?

Which payers have updated policy for code N39.498?

How do I get notified when code N39.498 policy changes?

Why do payers change policies for code N39.498?